ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Fan Lin(Utrecht University), Olaf van Tellingen(The Netherlands Cancer Institute), Mark C. de Gooijer(Manchester Academic Health Science Centre), Jos H. Beijnen(The Netherlands Cancer Institute), Levi C.M. Buil(Cancer Genomics Centre), Eloy Moreno Roig(Utrecht University), Jan H. Beumer(Johns Hopkins University), Thomas Würdinger(Amsterdam University Medical Centers), Susan M. Christner(Utrecht University)
Cited by 147
Related Papers
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
|The Journal of Experimental Medicine|2007|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial Cells
|Cancer Cell|2008|476
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451